PHARMASGP HOLDING SE O.N.
PHARMASGP HOLDING SE O.N./ DE000A2P4LJ5 /
PSG
03.06.2024 11:21:30
|
Zm.
-0,800
|
Wolumen |
Bid11:21:30 |
Ask11:21:30 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
21,600EUR
|
-3,57%
|
- Obrót: - |
21,600Wolumen Bid: - |
21,800Wolumen Ask: - |
273,6 mlnEUR |
1,97% |
25,62 |
Opis działalności
PharmaSGP is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side effects than most chemical-based pharmaceuticals. The Company’s core brands cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RUBAXX® for rheumatic pain and RESTAXIL® for neuralgic pain. Furthermore, PharmaSGP has introduced leading products against sexual weakness and vertigo symptoms.
Zarząd & Rada nadzorcza
CEO |
Natalie Weigand |
Zarząd |
Michael Rudolf |
Rada nadzorcza |
Dr. Clemens Fischer, Madlena Hohlefelder, Dr. Axel Rebien |
Dane firmy
Nazwa: |
PharmaSGP Holding SE |
Adres: |
Lochhamer Schlag 21,D-82166 Gräfelfing |
Telefon: |
+49-611-2058-5528 |
Fax: |
+49-611-2058-5566 |
E-mail: |
info@pharmasgp.com
|
Internet: |
https://pharmasgp.com/ |
Przemysł: |
Służba zdrowia |
Sektor: |
Przemysł Farmaceutyczny |
Podsektor: |
Przemysł Farmaceutyczny |
Koniec roku finansowego: |
31.12 |
Free float: |
- |
Data IPO: |
19.06.2020 |
Relacje inwestorskie
Nazwa: |
Claudius Krause |
Telefon: |
+49-611-2058-5535 |
Fax: |
- |
E-mail: |
ir@pharmasgp.com
|
Główni akcjonariusze
FUTRUE GmbH / MVH Beteiligungs- und Beratungs-GmbH |
|
77,82% |
Freefloat |
|
14,83% |
Union Investment Privatfonds GmbH |
|
4,70% |
Swedbank Robur Fonder AB |
|
2,65% |